On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer materials, a commercial for Bristol Myers Squibb’s Cobenfy is taking its turn in ...

Credit: Bristol Myers Squibb. Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors. Data from the EMERGENT ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in ...

The U.S. FDA's approval Thursday of Bristol Myers Squibb's (NYSE:BMY) novel antipsychotic Cobenfy (xanomeline and trospium chloride) for schizophrenia could significant influence treatment of the ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its challenger to Bristol Myers Squibb’s schizophrenia med Cobenfy. The ...

Cobenfy’s approval marks a critical shift in schizophrenia treatment. (Image Credits: Pixabay) The FDA has recently approved Karuna/Bristol Myers Squibb’s KarXT (Cobenfy), an oral medication for the ...

Bristol Myers BMY won FDA approval for xanomelineand trospiumchloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, in September 2024. The drug was approved under ...

29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria).

Adjunctive use of xanomeline/trospium chloride (Cobenfy) offered no statistically significant benefit over placebo in adults with symptoms of schizophrenia inadequately controlled by an atypical ...